Literature DB >> 17261770

Sex hormones and risk of liver tumor.

L Giannitrapani1, M Soresi, E La Spada, M Cervello, N D'Alessandro, G Montalto.   

Abstract

The liver is morphologically and functionally modulated by sex hormones. Long-term use of oral contraceptives (OCs) and anabolic androgenic steroids (AASs) can induce both benign (hemangioma, adenoma, and focal nodular hyperplasia [FNH]) and malignant (hepatocellular carcinoma [HCC]) hepatocellular tumors. Hepatic adenomas (HAs) are rare, benign neoplasms usually occurring in young women, the development and the complications of which have been related to the strength of OCs and the duration of their use. HA incidence has fallen since the introduction of pills containing smaller amounts of estrogens. FNH is a benign lesion, most commonly seen in young women, which is thought to represent a local hyperplastic response of hepatocytes to a vascular abnormality. Because of the female predominance and the young age at onset, a role of female hormones has been suggested. Furthermore, a large proportion of women with FNH (50-75%) are OC users. Liver hemangiomas (LHs) are the most common benign liver tumors and are seen more commonly in young adult females. The female predilection and clinical observations of LH growth under conditions of estrogenic exposure suggest a possible role for estrogen in the pathogenesis of LHs. HCC has become one of the most widespread tumors in the world in recent years, representing the sixth leading cancer and the third most common cause of death from cancer. Apart from liver cirrhosis, numerous other factors responsible for its onset have been proposed: hepatitis infections from virus B (HBV) and C (HCV), alcohol, smoking, and aflatoxin. However, regardless of etiology, chronic liver diseases progress at unequal rates in the two sexes, with the major sequelae, such as cirrhosis and HCC, being more frequent in men than in women. These epidemiological data have prompted researchers to investigate the relationship between sex hormones and liver tumors. The human liver expresses estrogen and androgen receptors and experimentally both androgens and estrogens have been implicated in stimulating hepatocyte proliferation and may act as liver tumor inducers or promoters.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17261770     DOI: 10.1196/annals.1386.044

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  83 in total

1.  Liver-specific ablation of Krüppel-associated box-associated protein 1 in mice leads to male-predominant hepatosteatosis and development of liver adenoma.

Authors:  Karolina Bojkowska; Fabio Aloisio; Marco Cassano; Adamandia Kapopoulou; Francesca Santoni de Sio; Nadine Zangger; Sandra Offner; Cristina Cartoni; Charles Thomas; Simon Quenneville; Kai Johnsson; Didier Trono
Journal:  Hepatology       Date:  2012-08-27       Impact factor: 17.425

Review 2.  Doping with anabolic androgenic steroids (AAS): Adverse effects on non-reproductive organs and functions.

Authors:  Eberhard Nieschlag; Elena Vorona
Journal:  Rev Endocr Metab Disord       Date:  2015-09       Impact factor: 6.514

3.  Oestrogen hormone receptors in focal nodular hyperplasia.

Authors:  Manju D Chandrasegaram; Ali Shah; John W Chen; Andrew Ruszkiewicz; David S Astill; Georgina England; Ravish S Raju; Eu Ling Neo; Paul M Dolan; Chuan Ping Tan; Mark Brooke-Smith; Tom Wilson; Robert T A Padbury; Christopher S Worthley
Journal:  HPB (Oxford)       Date:  2015-02-28       Impact factor: 3.647

4.  Cyclin D1 regulates hepatic estrogen and androgen metabolism.

Authors:  Lisa K Mullany; Eric A Hanse; Andrea Romano; Charles H Blomquist; J Ian Mason; Bert Delvoux; Chelsea Anttila; Jeffrey H Albrecht
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2010-03-25       Impact factor: 4.052

5.  FACS-assisted microarray profiling implicates novel genes and pathways in zebrafish gastrointestinal tract development.

Authors:  Carsten Stuckenholz; Lili Lu; Prakash Thakur; Naftali Kaminski; Nathan Bahary
Journal:  Gastroenterology       Date:  2009-06-27       Impact factor: 22.682

6.  Hepatic loss in a young patient: a very 'cold case'.

Authors:  Vincenzo De Francesco; Enzo Ierardi; Giuseppe Stoppino; Fabrizio Corsi; Maria Rosaria D'Agnessa; Michele Castriota; Cesare Hassan; Francesco Cianci; Angelo Zullo
Journal:  Intern Emerg Med       Date:  2011-03-23       Impact factor: 3.397

7.  Differential Proteomic Analysis of Gender-dependent Hepatic Tumorigenesis in Hras12V Transgenic Mice.

Authors:  Zhuona Rong; Tingting Fan; Huiling Li; Juan Li; Kangwei Wang; Xinxin Wang; Jianyi Dong; Jun Chen; Fujin Wang; Jingyu Wang; Aiguo Wang
Journal:  Mol Cell Proteomics       Date:  2017-05-16       Impact factor: 5.911

8.  Use of oral contraceptives, intrauterine devices and tubal sterilization and cancer risk in a large prospective study, from 1996 to 2006.

Authors:  Tsogzolmaa Dorjgochoo; Xiao-Ou Shu; Hong-Lan Li; Han-Zhu Qian; Gong Yang; Hui Cai; Yu-Tang Gao; Wei Zheng
Journal:  Int J Cancer       Date:  2009-05-15       Impact factor: 7.396

9.  Recurrent giant hemangiomas of liver: Report of two rare cases with literature review.

Authors:  Hongfa Zhu; Khaled Obeidat; Jie Ouyang; Sasan Roayaie; Myron E Schwartz; Swan N Thung
Journal:  World J Gastrointest Surg       Date:  2012-11-27

10.  Increase of hypophyseal hormone levels in male head and neck cancer patients.

Authors:  Eva Remenár; Irén Számel; Barna Budai; Borbála Vincze; István Gaudi; Sarolta Gundy; Miklós Kásler
Journal:  Pathol Oncol Res       Date:  2007-12-25       Impact factor: 3.201

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.